Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection

Medicine & Life Sciences

• Cohort Studies 10%
• Demography 5%
• Duration of Therapy 7%
• Exanthema 7%
• Fatigue 6%
• Fibrosis 11%
• Genotype 44%
• Guidelines 5%
• Headache 6%
• Hepacivirus 57%
• Infections 29%
• Interferons 7%
• Logistic Models 10%
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 12%
• Nausea 6%
• North America 8%
• Observational Studies 12%
• Protease Inhibitors 8%
• Ribavirin 70%
• RNA 5%
• Selection Bias 8%
• Simeprevir 100%
• Sleep Initiation and Maintenance Disorders 8%
• Sofosbuvir 90%
• Sustained Virologic Response 52%
• telaprevir 11%
• Therapeutics 10%